Patient characteristics
| Characteristic . | N (%) . |
|---|---|
| No. of patients | 152 |
| Patient age, y | |
| Median | 53 |
| Range | 18-71 |
| Patient sex | |
| Male | 89 |
| Female | 63 |
| Donor age, y | |
| Median | 31 |
| Range | 16-68 |
| Donor sex | |
| Male | 101 |
| Female | 51 |
| End of follow-up for all patients, d | |
| Median | 708 |
| Range | 53-2554 |
| End of follow-up for surviving patients, d | |
| Median | 1077 |
| Range | 89-2554 |
| Underlying disease | |
| AML | 78 (51.6) |
| ALL | 24 (15.6) |
| Other acute leukemia | 2 (1.3) |
| MDS | 14 (9.1) |
| CML/CMML | 7 (4.5) |
| MF | 4 (2.6) |
| MPN | 1 (0.6) |
| CLL/lymphoma | 19 (12.4) |
| Other hematological malignancy | 3 (1.9) |
| Disease risk* | |
| Good | 79 (52.2) |
| Poor | 73 (47.7) |
| Donor type† | |
| HLA-matched sibling | 55 (35.9) |
| 7-8/8 HLA-matched unrelated | 97 (63.9) |
| CMV serostatus, recipient/donor | |
| Positive/negative‡ | 20 (13.7) |
| All other | 131 (85.6) |
| Unknown | 1 (0.6) |
| No. of patients developing relapse | 30 (19.7) |
| No. of patients developing aGVHD, grade | |
| 2-4 | 39 (25.6) |
| 3-4 | 7 (4.6) |
| No. of patients developing cGVHD | |
| Moderate to severe | 19 (12.5) |
| Characteristic . | N (%) . |
|---|---|
| No. of patients | 152 |
| Patient age, y | |
| Median | 53 |
| Range | 18-71 |
| Patient sex | |
| Male | 89 |
| Female | 63 |
| Donor age, y | |
| Median | 31 |
| Range | 16-68 |
| Donor sex | |
| Male | 101 |
| Female | 51 |
| End of follow-up for all patients, d | |
| Median | 708 |
| Range | 53-2554 |
| End of follow-up for surviving patients, d | |
| Median | 1077 |
| Range | 89-2554 |
| Underlying disease | |
| AML | 78 (51.6) |
| ALL | 24 (15.6) |
| Other acute leukemia | 2 (1.3) |
| MDS | 14 (9.1) |
| CML/CMML | 7 (4.5) |
| MF | 4 (2.6) |
| MPN | 1 (0.6) |
| CLL/lymphoma | 19 (12.4) |
| Other hematological malignancy | 3 (1.9) |
| Disease risk* | |
| Good | 79 (52.2) |
| Poor | 73 (47.7) |
| Donor type† | |
| HLA-matched sibling | 55 (35.9) |
| 7-8/8 HLA-matched unrelated | 97 (63.9) |
| CMV serostatus, recipient/donor | |
| Positive/negative‡ | 20 (13.7) |
| All other | 131 (85.6) |
| Unknown | 1 (0.6) |
| No. of patients developing relapse | 30 (19.7) |
| No. of patients developing aGVHD, grade | |
| 2-4 | 39 (25.6) |
| 3-4 | 7 (4.6) |
| No. of patients developing cGVHD | |
| Moderate to severe | 19 (12.5) |
aGVHD, acute GVHD; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; cGVHD, chronic GVHD; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; CMV, cytomegalovirus; MDS, myelodysplastic syndrome; MF, myelofibrosis; MPN, myeloproliferative neoplasms.
Good risk was defined as acute leukemia (AML, ALL, biphenotypic) in first remission, CML in first chronic or accelerated phase, myelodysplasia with <5% blasts in the marrow, or aplastic anemia. All other diseases/disease stages were considered poor risk.
Of the 97 donors, 30 were 7/8 HLA-matched unrelated donors, and 66 were 8/8 matched unrelated donors. This group also contains 1 7/8 HLA-matched related donor.
Poor-prognosis group.24